113 results
424B5
ENVB
Enveric Biosciences Inc
3 May 24
Prospectus supplement for primary offering
5:05pm
that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance … Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability of EB-002. EB-002
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
26 Mar 24
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
8:00am
and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies.
Corporate … studies, as well as cardiac, respiratory markers, and CNS safety pharmacology studies. We expect to finalize all preclinical activities for EB-002 soon
424B5
3wzxgqpqtw9z948jtcf9
11 Mar 24
Prospectus supplement for primary offering
12:35pm
424B3
e7721rqj7
24 Jan 24
Prospectus supplement
8:05am
8-K
65z xa58pjy
27 Dec 23
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
8:05am
8-K
EX-99.1
j31a8ll36u
27 Dec 23
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
8:05am
424B4
nfxz87
6 Dec 23
Prospectus supplement with pricing info
4:00pm
8-K
EX-99.1
ohxv2duvxkf3u8jk6gq
13 Nov 23
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
4:10pm
8-K
EX-10.1
2s3iof8hky xsr0tmlp
6 Nov 23
Entry into a Material Definitive Agreement
8:05am
8-K
89c fhto9l8
18 Oct 23
Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373
8:05am
8-K
EX-99.1
6jm70v92owlu1c8qp
18 Oct 23
Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373
8:05am